Product Description
9MW2921 is a next generation Antibody-Drug Conjugate (ADC) developed by Mabwell based on IDDC™ (Interchain-Disulfide Drug Conjugate) platform for the treatment of solid tumors. It is an innovative antibody molecule linked to a novel payload (TOP1i) by a novel linker with fully autonomous intellectual property right. When 9MW2921 enters into the body, it can specifically bind to antigens on the cell membrane surface, be internalized and trafficked to the lysosome, release cytotoxic drug and induce the apoptosis of tumor cells. (Sourced from: https://www.mabwell.com/en/news_info/id-93.html)
Mechanisms of Action: TOP1 Inhibitor
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mabwell (Shanghai) Bioscience
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
9MW2921-2023-CP101 | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2026-09-01 |
57% |